Through an innovative production model with strategic alliances with national and international labortories, Sinergium Biotech develops, produces and commercializes vaccines and highly complex biotechnology products.
In alliance with the Swiss company Novartis, world leader in Research and Development, and one of the largest producers of influenza vaccines worldwide, the technology transfer for the local production of influenza vaccines is carried out. This transfer makes Argentina be part of a reduced group of countries with the necessary technology for the development, production and marketing of this vaccine. The production capacity of Sinergium Biotech allows stocking up on the needs of both Southern and Northern hemispheres.
Along with Pfizer, the largest biopharmaceutical company worldwide, the technology transfer is agreed for the national production and supply of the pneumococcal conjugate vaccine, a highly complex and technologically advanced product. Its production requires the formulation of several of the most common pneumococcal serotypes in one single product. The complete production process takes about a year and the final presentation is in pre-filled syringes. Argentina is the only country in Latin America, and one of the few in the world, that formulates and has the capacity to produce this vaccine.
Likewise, and with the objective of contributing to reduce the incidence and mortality of cervical cancer in Argentina, Sinergium Biotech developed a strategic alliance with MSD (Merck, Sharp & Dohme), Argentine subsidiary of the American pharmaceutical company Merck & Co, for the production of the tetravalent vaccine that prevents the infection against four virus strains; 6, 11 (that causes 90% of all the cases of genital warts), 16 and 18 (responsible for 77% of the cases of cervical cancer1). Argentina will be one of the few countries with the capacity to produce this vaccine.
For the production of monoclonal antibodies, Sinergium Biotech joins with Laboratorio Elea, Chemo – with its biotechnology company mAbxcience – and pharmADN making a public-private partnership with Instituto Roffo (UBA), Universidad de Quilmes and MinCyT for the development and production of active ingredients of monoclonal antibodies. As the result of a productive alliance, Sinergium Biotech performs the formulation, packing and packaging of these biotechnology products in a dedicated are with the highest international quality standards of the Good Manufacturing Practices (GMP – for its initials in English).
The production line of biosimilar products uses raw materials and processes strictly validated and monitored by a group of highly qualified professionals and technicians. The premises and infrastructure comply with the highest quality standards and count with state-of-the-art equipment for the formulation, filling and inspection of these products.
September 11, 2016
Strategic alliances for the development of innovative products